Switch theme
Sign up to access all valuation multiples
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
2000
575
LTM Revenue $155M
LTM EBITDA -$213M
$644M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Pacific Biosciences has a last 12-month revenue (LTM) of $155M and a last 12-month EBITDA of -$213M.
In the most recent fiscal year, Pacific Biosciences achieved revenue of $154M and an EBITDA of -$243M.
Pacific Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Pacific Biosciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $155M | XXX | $154M | XXX | XXX | XXX |
| Gross Profit | $42.3M | XXX | $37.3M | XXX | XXX | XXX |
| Gross Margin | 27% | XXX | 24% | XXX | XXX | XXX |
| EBITDA | -$213M | XXX | -$243M | XXX | XXX | XXX |
| EBITDA Margin | -137% | XXX | -158% | XXX | XXX | XXX |
| EBIT | -$223M | XXX | -$291M | XXX | XXX | XXX |
| EBIT Margin | -144% | XXX | -189% | XXX | XXX | XXX |
| Net Profit | -$382M | XXX | -$310M | XXX | XXX | XXX |
| Net Margin | -247% | XXX | -201% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $592M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Pacific Biosciences's stock price is $1.
Pacific Biosciences has current market cap of $288M, and EV of $644M.
See Pacific Biosciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $644M | $288M | XXX | XXX | XXX | XXX | $-1.12 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Pacific Biosciences has market cap of $288M and EV of $644M.
Pacific Biosciences's trades at 4.2x EV/Revenue multiple, and -2.7x EV/EBITDA.
Equity research analysts estimate Pacific Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Pacific Biosciences has a P/E ratio of -0.8x.
See valuation multiples for Pacific Biosciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $288M | XXX | $288M | XXX | XXX | XXX |
| EV (current) | $644M | XXX | $644M | XXX | XXX | XXX |
| EV/Revenue | 4.2x | XXX | 4.2x | XXX | XXX | XXX |
| EV/EBITDA | -3.0x | XXX | -2.7x | XXX | XXX | XXX |
| EV/EBIT | -2.9x | XXX | -2.2x | XXX | XXX | XXX |
| EV/Gross Profit | 15.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.8x | XXX | -0.9x | XXX | XXX | XXX |
| EV/FCF | -3.2x | XXX | -3.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPacific Biosciences's last 12 month revenue growth is 9%
Pacific Biosciences's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.6M for the same period.
Pacific Biosciences's rule of 40 is -130% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Pacific Biosciences's rule of X is -116% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Pacific Biosciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | -137% | XXX | -158% | XXX | XXX | XXX |
| EBITDA Growth | -45% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -130% | XXX | -149% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -116% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 88% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 213% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pacific Biosciences acquired XXX companies to date.
Last acquisition by Pacific Biosciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Pacific Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Pacific Biosciences founded? | Pacific Biosciences was founded in 2000. |
| Where is Pacific Biosciences headquartered? | Pacific Biosciences is headquartered in United States of America. |
| How many employees does Pacific Biosciences have? | As of today, Pacific Biosciences has 575 employees. |
| Who is the CEO of Pacific Biosciences? | Pacific Biosciences's CEO is Mr. Christian O. Henry. |
| Is Pacific Biosciences publicy listed? | Yes, Pacific Biosciences is a public company listed on NAS. |
| What is the stock symbol of Pacific Biosciences? | Pacific Biosciences trades under PACB ticker. |
| When did Pacific Biosciences go public? | Pacific Biosciences went public in 2010. |
| Who are competitors of Pacific Biosciences? | Similar companies to Pacific Biosciences include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Pacific Biosciences? | Pacific Biosciences's current market cap is $288M |
| What is the current revenue of Pacific Biosciences? | Pacific Biosciences's last 12 months revenue is $155M. |
| What is the current revenue growth of Pacific Biosciences? | Pacific Biosciences revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Pacific Biosciences? | Current revenue multiple of Pacific Biosciences is 4.2x. |
| Is Pacific Biosciences profitable? | Yes, Pacific Biosciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Pacific Biosciences? | Pacific Biosciences's last 12 months EBITDA is -$213M. |
| What is Pacific Biosciences's EBITDA margin? | Pacific Biosciences's last 12 months EBITDA margin is -137%. |
| What is the current EV/EBITDA multiple of Pacific Biosciences? | Current EBITDA multiple of Pacific Biosciences is -3.0x. |
| What is the current FCF of Pacific Biosciences? | Pacific Biosciences's last 12 months FCF is -$200M. |
| What is Pacific Biosciences's FCF margin? | Pacific Biosciences's last 12 months FCF margin is -129%. |
| What is the current EV/FCF multiple of Pacific Biosciences? | Current FCF multiple of Pacific Biosciences is -3.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
